Chronic lymphocytic leukemia: A clinical and molecular heterogenous disease

Cancer Genetics

Volumn 206, Issue 3, 2013, Pages 49-62

  Rodríguez Vicente, Ana E ^a   Díaz, Marcos González ^a,b   Hernández Rivas, Jesús M ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Chronic lymphocytic leukemia; Cytogenetic aberrations; FISH; Next generation sequencing

Indexed keywords

ALEMTUZUMAB; MICRORNA; MICRORNA 181A; MICRORNA 181B; MICRORNA 21; MICRORNA 223; MICRORNA 29C; MICRORNA 34; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME DELETION 11Q; CHROMOSOME DELETION 13Q; CHROMOSOME DELETION 17P; CHROMOSOME DELETION 6Q; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; KARYOTYPING; METAPHASE CHROMOSOME; NEXT GENERATION SEQUENCING; NOTCH1 GENE; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SEQUENCE ANALYSIS; SF3B1 GENE; SURVIVAL PREDICTION; TCL1 GENE; TRISOMY 12; TUMOR SUPPRESSOR GENE; ZETA CHAIN ASSOCIATED PROTEIN KINASE 70 GENE;

CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DNA METHYLATION; GENETIC HETEROGENEITY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; MUTATION; PHOSPHOPROTEINS; PROGNOSIS; RECEPTOR, NOTCH1; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR;

EID: 84875904187     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2013.01.003     Document Type: Review

References (200)

1. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
2. Rozman C., Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995, 333:1052-1057.
3. Zwiebel J.A., Cheson B.D. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 1998, 25:42-59.
4. Watson L., Wyld P., Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol 2008, 81:253-258.
5. Dighiero G., Hamblin T.J. Chronic lymphocytic leukaemia. Lancet 2008, 371:1017-1029.
6. Matutes E., Owusu-Ankomah K., Morilla R., et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994, 8:1640-1645.
7. Matutes E., Morilla R., Owusu-Ankomah K., et al. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994, 83:1558-1562.
8. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007, 20:399-413.
9. Messmer B.T., Messmer D., Allen S.L., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005, 115:755-764.
10. Sieklucka M., Pozarowski P., Bojarska-Junak A., et al. Apoptosis in B-CLL: the relationship between higher ex vivo spontaneous apoptosis before treatment in III-IV Rai stage patients and poor outcome. Oncol Rep 2008, 19:1611-1620.
11. Wierda W.G., O'Brien S., Wang X., et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007, 109:4679-4685.
12. Dighiero G., Binet J.L. When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000, 343:1799-1801.
13. Giles F.J., O'Brien S.M., Keating M.J. Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol 1998, 25:117-125.
14. Cuneo A., De A.C., Roberti M.G., et al. Richter's syndrome in a case of atypical chronic lymphocytic leukaemia with the t(11;14)(q13;q32): role for a p53 exon 7 gene mutation. Br J Haematol 1996, 92:375-381.
15. Hercher C., Robain M., Davi F., et al. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 2001, 42:981-987.
16. Lens D., Coignet L.J., Brito-Babapulle V., et al. B cell prolymphocytic leukaemia (B-PLL) with complex karyotype and concurrent abnormalities of the p53 and c-MYC gene. Leukemia 1999, 13:873-876.
17. Juliusson G., Oscier D.G., Fitchett M., et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990, 323:720-724.
18. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
19. Mayr C., Speicher M.R., Kofler D.M., et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006, 107:742-751.
20. Hernandez J.A., Rodriguez A.E., Gonzalez M., et al. A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica 2009, 94:364-371.
21. Hernandez J.M., Mecucci C., Criel A., et al. Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria. Leukemia 1995, 9:2140-2146.
22. Dicker F., Schnittger S., Haferlach T., et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006, 108:3152-3160.
23. Zenz T., Mertens D., Kuppers R., et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010, 10:37-50.
24. Lichter P., Cremer T., Borden J., et al. Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization using recombinant DNA libraries. Hum Genet 1988, 80:224-234.
25. Finn W.G., Kay N.E., Kroft S.H., et al. Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients. Am J Hematol 1998, 59:223-229.
26. Fegan C., Robinson H., Thompson P., et al. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995, 9:2003-2008.
27. Cuneo A., Bigoni R., Rigolin G.M., et al. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. Haematologica 2002, 87:44-51.
28. Stilgenbauer S., Sander S., Bullinger L., et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007, 92:1242-1245.
29. Stilgenbauer S., Bullinger L., Lichter P., et al. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002, 16:993-1007.
30. Berkova A., Zemanova Z., Trneny M., et al. Clonal evolution in chronic lymphocytic leukemia studied by interphase fluorescence in-situ hybridization. Neoplasma 2009, 56:455-458.
31. Lehmann S., Ogawa S., Raynaud S.D., et al. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer 2008, 112:1296-1305.
32. Schwaenen C., Nessling M., Wessendorf S., et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A 2004, 101:1039-1044.
33. Pfeifer D., Pantic M., Skatulla I., et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007, 109:1202-1210.
34. Gunn S.R., Mohammed M.S., Gorre M.E., et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chroniclymphocytic leukemia. J Mol Diagn 2008, 10:442-451.
35. Sargent R., Jones D., Abruzzo L.V., et al. Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn 2009, 11:25-34.
36. de Leeuw R.J., Davies J.J., Rosenwald A., et al. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet 2004, 13:1827-1837.
37. Kohlhammer H., Schwaenen C., Wessendorf S., et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004, 104:795-801.
38. Rubio-Moscardo F., Climent J., Siebert R., et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005, 105:4445-4454.
39. Tyybakinoja A., Saarinen-Pihkala U., Elonen E., et al. Amplified, lost, and fused genes in 11q23-25 amplicon in acute myeloid leukemia, an array-CGH study. Genes Chromosomes Cancer 2006, 45:257-264.
40. Tyybakinoja A., Vilpo J., Knuutila S. High-resolution oligonucleotide array-CGH pinpoints genes involved in cryptic losses in chronic lymphocytic leukemia. Cytogenet Genome Res 2007, 118:8-12.
41. Patel A., Kang S.H., Lennon P.A., et al. Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia. Am J Hematol 2008, 83:540-546.
42. Grubor V., Krasnitz A., Troge J.E., et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 2009, 113:1294-1303.
43. Gunn S.R., Bolla A.R., Barron L.L., et al. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res 2009, 33:1276-1281.
44. Forconi F., Rinaldi A., Kwee I., et al. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. Br J Haematol 2008, 143:532-536.
45. Rodriguez A.E., Robledo C., Garcia J.L., et al. Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling. Ann Oncol 2012.
46. Kujawski L., Ouillette P., Erba H., et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 2008, 112:1993-2003.
47. Kay N.E., Eckel-Passow J.E., Braggio E., et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet 2010, 203:161-168.
48. Kipps T.J. Genomic complexity in chronic lymphocytic leukemia. Blood 2008, 112:1550.
49. Gunnarsson R., Mansouri L., Isaksson A., et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 2011, 96:1161-1169.
50. Ouillette P., Erba H., Kujawski L., et al. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008, 68:1012-1021.
51. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
52. Van B.F., Verhasselt B., Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009, 23:25-47.
53. Shanafelt T.D., Witzig T.E., Fink S.R., et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006, 24:4634-4641.
54. Rodriguez A.E., Hernandez J.A., Benito R., et al. Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14. PLoS One 2012, 7:e48485.
55. Van Dyke D.L., Shanafelt T.D., Call T.G., et al. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol 2010, 148:544-550.
56. Dal B.M., Rossi F.M., Rossi D., et al. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes Cancer 2011, 50:633-643.
57. Mosca L., Fabris S., Lionetti M., et al. Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. Clin Cancer Res 2010, 16:5641-5653.
58. Bullrich F., Fujii H., Calin G., et al. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 2001, 61:6640-6648.
59. Liu Y., Corcoran M., Rasool O., et al. Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 1997, 15:2463-2473.
60. Migliazza A., Bosch F., Komatsu H., et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001, 97:2098-2104.
61. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
62. Parker H., Rose-Zerilli M.J., Parker A., et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia 2011, 25:489-497.
63. Hanlon K., Ellard S., Rudin C.E., et al. Evaluation of 13q14 status in patients with chronic lymphocytic leukemia using single nucleotide polymorphism-based techniques. J Mol Diagn 2009, 11:298-305.
64. Garg R., Wierda W., Ferrajoli A., et al. The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer 2012, 118:3531-3537.
65. Mertens D., Wolf S., Tschuch C., et al. Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. Proc Natl Acad Sci U S A 2006, 103:7741-7746.
66. Calin G.A., Cimmino A., Fabbri M., et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 2008, 105:5166-5171.
67. Garzon R., Calin G.A., Croce C.M. MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179.
68. Raveche E.S., Salerno E., Scaglione B.J., et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007, 109:5079-5086.
69. Klein U., Lia M., Crespo M., et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010, 17:28-40.
70. Cimmino A., Calin G.A., Fabbri M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005, 102:13944-13949.
71. Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
72. Zenz T., Vollmer D., Trbusek M., et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010, 24:2072-2079.
73. Matutes E., Oscier D., Garcia-Marco J., et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996, 92:382-388.
74. Merup M., Juliusson G., Wu X., et al. Amplification of multiple regions of chromosome 12, including 12q13-15, in chronic lymphocytic leukaemia. Eur J Haematol 1997, 58:174-180.
75. Josefsson P., Geisler C.H., Leffers H., et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 2007, 109:4973-4979.
76. Buhl A.M., Jurlander J., Jorgensen F.S., et al. Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. Blood 2006, 107:2904-2911.
77. Dohner H., Stilgenbauer S., James M.R., et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997, 89:2516-2522.
78. Catovsky D., Richards S., Matutes E., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230-239.
79. Marasca R., Maffei R., Martinelli S., et al. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematol Oncol 2012, [Epub ahead of print].
80. Lavin M.F. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008, 9:759-769.
81. Fiegl M., Erdel M., Tinhofer I., et al. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol 2010, 21:2410-2419.
82. Dicker F., Herholz H., Schnittger S., et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009, 23:117-124.
83. Rossi D., Cerri M., Deambrogi C., et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009, 15:995-1004.
84. Zenz T., Krober A., Scherer K., et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008, 112:3322-3329.
85. Dohner H., Fischer K., Bentz M., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995, 85:1580-1589.
86. Oscier D., Wade R., Davis Z., et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010, 95:1705-1712.
87. Tam C.S., Shanafelt T.D., Wierda W.G., et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009, 114:957-964.
88. Zenz T., Eichhorst B., Busch R., et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010, 28:4473-4479.
89. Gonzalez D., Martinez P., Wade R., et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011, 29:2223-2229.
90. Zenz T., Habe S., Denzel T., et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009, 114:2589-2597.
91. Cuneo A., Rigolin G.M., Bigoni R., et al. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. Leukemia 2004, 18:476-483.
92. Stilgenbauer S., Bullinger L., Benner A., et al. Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia. Leukemia 1999, 13:1331-1334.
93. Karakosta M., Tsakiridou A., Korantzis I., et al. Deletion of 5q as a rare abnormality in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2010, 200:175-179.
94. Haferlach C., Dicker F., Schnittger S., et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007, 21:2442-2451.
95. Cavazzini F., Hernandez J.A., Gozzetti A., et al. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol 2008, 142:529-537.
96. Ouillette P., Collins R., Shakhan S., et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 2011, 118:3051-3061.
97. Gunnarsson R., Isaksson A., Mansouri M., et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2010, 24:211-215.
98. Rigolin G.M., Cibien F., Martinelli S., et al. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with " normal" FISH: correlations with clinicobiologic parameters. Blood 2012, 119:2310-2313.
99. Dewald G.W., Brockman S.R., Paternoster S.F., et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003, 121:287-295.
100. Chevallier P., Penther D., vet-Loiseau H., et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002, 116:142-150.
101. Gribben J.G. How I treat CLL up front. Blood 2010, 115:187-197.
102. Mougalian S.S., O'Brien S. Adverse prognostic features in chronic lymphocytic leukemia. Oncology (Williston Park) 2011, 25:692-696. 699.
103. Hillmen P., Skotnicki A.B., Robak T., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616-5623.
104. Pettitt A.R., Jackson R., Carruthers S., et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the National Cancer Research Institute CLL206 Trial. J Clin Oncol 2012, 30:1647-1655.
105. Reeder C.B., Ansell S.M. Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood 2011, 117:1453-1462.
106. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012, 120:4684-4691.
107. Tam C.S., Otero-Palacios J., Abruzzo L.V., et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 2008, 141:36-40.
108. Matutes E., Carrara P., Coignet L., et al. FISH analysis for BCL-1 rearrangements and trisomy 12 helps the diagnosis of atypical B cell leukaemias. Leukemia 1999, 13:1721-1726.
109. Brito-Babapulle V., Ellis J., Matutes E., et al. Translocation t(11;14)(q13;q32) in chronic lymphoid disorders. Genes Chromosomes Cancer 1992, 5:158-165.
110. Cuneo A., Bigoni R., Negrini M., et al. Cytogenetic and interphase cytogenetic characterization of atypical chronic lymphocytic leukemia carrying BCL1 translocation. Cancer Res 1997, 57:1144-1150.
111. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
112. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
113. Schroeder H.W., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994, 15:288-294.
114. Lanham S., Hamblin T., Oscier D., et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003, 101:1087-1093.
115. Magnac C., Porcher R., Davi F., et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 2003, 17:133-137.
116. Krober A., Seiler T., Benner A., et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002, 100:1410-1416.
117. Jelinek D.F., Tschumper R.C., Geyer S.M., et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001, 115:854-861.
118. Hamblin T.J., Orchard J.A., Ibbotson R.E., et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002, 99:1023-1029.
119. Oscier D.G., Gardiner A.C., Mould S.J., et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002, 100:1177-1184.
120. Grever M.R., Lucas D.M., Johnson A.J., et al. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007, 20:545-556.
121. Ritgen M., Lange A., Stilgenbauer S., et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003, 101:2049-2053.
122. Smit L.A., van M.F., Langerak A.W., et al. Antigen receptors and somatic hypermutation in B-cell chronic lymphocytic leukemia with Richter's transformation. Haematologica 2006, 91:903-911.
123. Lin K., Sherrington P.D., Dennis M., et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002, 100:1404-1409.
124. Ghia P., Stamatopoulos K., Belessi C., et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005, 105:1678-1685.
125. Capello D., Guarini A., Berra E., et al. Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. Leukemia 2004, 18:1941-1947.
126. Capello D., Zucchetto A., Degan M., et al. Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Res 2006, 30:1197-1199.
127. Dal-Bo M., Del G.I., Bomben R., et al. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. Br J Haematol 2011, 153:3-14.
128. Montillo M., Hamblin T., Hallek M., et al. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 2005, 90:391-399.
129. Rosenwald A., Alizadeh A.A., Widhopf G., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1647.
130. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764-1775.
131. Wiestner A., Rosenwald A., Barry T.S., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003, 101:4944-4951.
132. Orchard J.A., Ibbotson R.E., Davis Z., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004, 363:105-111.
133. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351:893-901.
134. Wattel E., Preudhomme C., Hecquet B., et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994, 84:3148-3157.
135. Cordone I., Masi S., Mauro F.R., et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998, 91:4342-4349.
136. Austen B., Skowronska A., Baker C., et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007, 25:5448-5457.
137. Austen B., Powell J.E., Alvi A., et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005, 106:3175-3182.
138. Bullrich F., Rasio D., Kitada S., et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999, 59:24-27.
139. Puente X.S., Pinyol M., Quesada V., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
140. Quesada V., Conde L., Villamor N., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011, 44:47-52.
141. Wang L., Lawrence M.S., Wan Y., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011, 365:2497-2506.
142. Fabbri G., Rasi S., Rossi D., et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011, 208:1389-1401.
143. Rosati E., Sabatini R., Rampino G., et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009, 113:856-865.
144. Villamor N., Conde L., Martinez-Trillos A., et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2012, [Epub ahead of print].
145. Rossi D., Rasi S., Fabbri G., et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012, 119:521-529.
146. Balatti V., Bottoni A., Palamarchuk A., et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012, 119:329-331.
147. Del Giudice I., Rossi D., Chiaretti S., et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 2012, 97:437-441.
148. Lopez C., Delgado J., Costa D., et al. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes Cancer 2012, 51:881-889.
149. Paganin M., Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011, 25:83-90.
150. Papaemmanuil E., Cazzola M., Boultwood J., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365:1384-1395.
151. Rossi D., Bruscaggin A., Spina V., et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011, 118:6904-6908.
152. Rossi D., Fangazio M., Rasi S., et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012, 119:2854-2862.
153. Compagno M., Lim W.K., Grunn A., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
154. Schuh A., Becq J., Humphray S., et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 2012.
155. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
156. Grimson A., Farh K.K., Johnston W.K., et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007, 27:91-105.
157. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
158. Calin G.A., Liu C.G., Sevignani C., et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004, 101:11755-11760.
159. Calin G.A., Ferracin M., Cimmino A., et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
160. Fulci V., Chiaretti S., Goldoni M., et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007, 109:4944-4951.
161. Zanette D.L., Rivadavia F., Molfetta G.A., et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res 2007, 40:1435-1440.
162. Zhang J., Jima D.D., Jacobs C., et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009, 113:4586-4594.
163. Stamatopoulos B., Meuleman N., Haibe-Kains B., et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009, 113:5237-5245.
164. Rossi S., Shimizu M., Barbarotto E., et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010, 116:945-952.
165. Visone R., Rassenti L.Z., Veronese A., et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009, 114:3872-3879.
166. Fabbri M., Bottoni A., Shimizu M., et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011, 305:59-67.
167. Stach D., Schmitz O.J., Stilgenbauer S., et al. Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 2003, 31:E2.
168. Lyko F., Stach D., Brenner A., et al. Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients. Electrophoresis 2004, 25:1530-1535.
169. Wahlfors J., Hiltunen H., Heinonen K., et al. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood 1992, 80:2074-2080.
170. Robertson K.D., Jones P.A. DNA methylation: past, present and future directions. Carcinogenesis 2000, 21:461-467.
171. Rahmatpanah F.B., Carstens S., Hooshmand S.I., et al. Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenomics 2009, 1:39-61.
172. Rush L.J., Raval A., Funchain P., et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 2004, 64:2424-2433.
173. Hanada M., Delia D., Aiello A., et al. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993, 82:1820-1828.
174. Yuille M.R., Condie A., Stone E.M., et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer 2001, 30:336-341.
175. Lipsanen V., Leinonen P., Alhonen L., et al. Hypomethylation of ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia. Blood 1988, 72:2042-2044.
176. Raval A., Lucas D.M., Matkovic J.J., et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 2005, 23:3877-3885.
177. Corcoran M., Parker A., Orchard J., et al. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 2005, 90:1078-1088.
178. Claus R., Lucas D.M., Stilgenbauer S., et al. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol 2012, 30:2483-2491.
179. Raval A., Tanner S.M., Byrd J.C., et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007, 129:879-890.
180. Tsirigotis P., Pappa V., Labropoulos S., et al. Mutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia. Eur J Haematol 2006, 76:230-236.
181. Papageorgiou S.G., Lambropoulos S., Pappa V., et al. Hypermethylation of the p15INK4B gene promoter in B-chronic lymphocytic leukemia. Am J Hematol 2007, 82:824-825.
182. Yu M.K., Bergonia H., Szabo A., et al. Progressive disease in chronic lymphocytic leukemia is correlated with the DNA methylation index. Leuk Res 2007, 31:773-777.
183. Kulis M., Heath S., Bibikova M., et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012, 44:1236-1242.
184. Kanduri M., Cahill N., Goransson H., et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 2010, 115:296-305.
185. Nana-Sinkam S.P., Croce C.M. MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application. Cancer Genet Cytogenet 2010, 203:127-133.
186. Nicoloso M.S., Kipps T.J., Croce C.M., et al. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol 2007, 139:709-716.
187. Mertens D., Wolf S., Schroeter P., et al. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood 2002, 99:4116-4121.
188. Pallasch C.P., Patz M., Park Y.J., et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 2009, 114:3255-3264.
189. Patz M., Pallasch C.P., Wendtner C.M. Critical role of microRNAs in chronic lymphocytic leukemia: overexpression of the oncogene PLAG1 by deregulated miRNAs. Leuk Lymphoma 2010, 51:1379-1381.
190. Wong K.Y., So C.C., Loong F., et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 2011, 6:e19027.
191. Fabbri M., Garzon R., Cimmino A., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007, 104:15805-15810.
192. Mercurio C., Minucci S., Pelicci P.G. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010, 62:18-34.
193. Blum K.A., Advani A., Fernandez L., et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009, 147:507-514.
194. Heerema N.A., Byrd J.C., Dal Cin P.S., et al. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet 2010, 203:134-140.
195. Put N., Konings P., Rack K., et al. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer 2009, 48:843-853.
196. Grever M.R., Lucas D.M., Dewald G.W., et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007, 25:799-804.
197. Quijano S., Lopez A., Rasillo A., et al. Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. Blood 2008, 111:5130-5141.
198. Hagenkord J.M., Monzon F.A., Kash S.F., et al. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays. J Mol Diagn 2010, 12:184-196.
199. O'Malley D.P., Giudice C., Chang A.S., et al. Comparison of array comparative genomic hybridization (aCGH) to FISH and cytogenetics in prognostic evaluation of chronic lymphocytic leukemia. Int J Lab Hematol 2011, 33:238-244.
200. Rinaldi A., Mian M., Kwee I., et al. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. Br J Haematol 2011, 154:590-599.